Stingfree AB’s PROTEX® Nicotine Pouch Technology Validated in Groundbreaking Oral Health Study

Stingfree AB proudly announces the publication of a peer-reviewed pilot study validating the oral health benefits of its proprietary PROTEX® nicotine pouch technology. Published in Acta Odontologica Scandinavica, the study demonstrates significant reductions in oral lesions and gingival irritation following a five-week trial using the Stingfree Strong Blue Mint pouch, which incorporates PROTEX®‘s innovative protective barrier.

The study, led by researchers at the University of Catania and involving 23 Swedish dentists who regularly use nicotine pouches or snus, is the first of its kind to evaluate user-reported oral health outcomes with a focus on a product designed to reduce mucosal irritation. Notably, the study found a 27.3% reduction in snus lesion prevalence, a complete elimination of self-reported gingivitis (gum inflammation), and a 90% decrease in gum irritation. No participants experienced worsened oral lesions, and none remained in the most severe lesion category after the study period.

Stingfree’s PROTEX® technology features an impermeable barrier designed to shield the gums from direct contact with nicotine and pouch ingredients while preserving the sensory experience and nicotine release. This technology addresses one of the most common concerns among oral nicotine pouch users: localized irritation and lesion development.

“We are thrilled to see clinical validation of our technology in a population of dental professionals. This study marks an important milestone in our mission to reduce harm and improve user comfort in the nicotine pouch category.” – Daniel Wiberg, CEO Stingfree AB

The study offers compelling evidence supporting the PROTEX® pouch’s role in reducing oral health issues common to the use of snus and nicotine pouches.

The full study is available online through Acta Odontologica Scandinavica and National Library of Medicine (PubMed®).